Compare EXPI & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EXPI | EVO |
|---|---|---|
| Founded | 2008 | 1993 |
| Country | United States | Germany |
| Employees | N/A | 4553 |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 934.1M |
| IPO Year | 2010 | N/A |
| Metric | EXPI | EVO |
|---|---|---|
| Price | $6.76 | $2.78 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $9.75 | $7.00 |
| AVG Volume (30 Days) | ★ 870.8K | 91.4K |
| Earning Date | 05-11-2026 | 04-08-2026 |
| Dividend Yield | ★ 3.18% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $500,147,681.00 | N/A |
| Revenue This Year | $6.26 | $1.37 |
| Revenue Next Year | $5.50 | $10.05 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 220.39 | N/A |
| 52 Week Low | $5.66 | $2.31 |
| 52 Week High | $12.23 | $4.80 |
| Indicator | EXPI | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 60.03 | 45.59 |
| Support Level | $5.68 | $2.63 |
| Resistance Level | $6.87 | $3.78 |
| Average True Range (ATR) | 0.23 | 0.09 |
| MACD | 0.04 | -0.04 |
| Stochastic Oscillator | 81.56 | 31.23 |
eXp World Holdings Inc is a cloud-based residential real estate company. The company owns and operates a cloud-based real estate brokerage and a technology platform business that develops and uses immersive technologies that help businesses increase their effectiveness and reduce costs from operating in traditional brick-and-mortar office spaces. Its business categories include Real Estate Brokerage, Technology Products and Services, Title, Escrow, Settlement Services, and Mortgage Brokerage Services.
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.